April 1, 2024 Issue of JAMA Oncology

April 2024, Vol 10, No. 4, Pages 423-543

Original Investigation

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non鈥揝mall Cell Lung Cancer

Yoko Tsukita, MD, PhD; Takehiro Tozuka, MD; Kohei Kushiro, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(4):439-447. doi:10.1001/jamaoncol.2023.6277

This case series assesses overall and progression-free survival and safety outcomes of chemotherapy and immunotherapy combination treatment in patients 75 years and older with non鈥搒mall cell lung cancer.

Editorial
Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice
Elad Sharon, MD, MPH

JAMA Oncol

Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor鈥揜elated Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial

Shaohua Zhang, MD; Yongmei Yin, MD; Hailin Xiong, MD; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(4):448-455. doi:10.1001/jamaoncol.2023.6520

This clinical trial examines the safety, efficacy, and biosimilarity of MW032 compared with denosumab in patients with solid tumor鈥搑elated bone metastases.

Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial

Jinxuan Dai, MD; Bin Zhang, MD; Yixin Su, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(4):456-463. doi:10.1001/jamaoncol.2023.6552

This randomized clinical trial examines if radiotherapy is noninferior to chemoradiotherapy after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Hyperbaric Oxygen Therapy and Late Local Toxic Effects in Patients With Irradiated Breast Cancer: A Randomized Clinical Trial

Dieuwke R. Mink van der Molen, PhD; Marilot C. T. Batenburg, MD, PhD; Wiesje Maarse, MD, PhD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(4):464-474. doi:10.1001/jamaoncol.2023.6776

This randomized clinical trial assesses effectiveness of hyperbaric oxygen therapy for late local toxic effects in women who received adjuvant radiotherapy for breast cancer.

Editorial
Hyperbaric Oxygen Therapy for Management of Late Radiation Toxicity鈥擜 Honey of a Trial?
Ezra Hahn, MD; Aron Popovtzer, MD; Benjamin W. Corn, MD

JAMA Oncol

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial

Peter W. Szlosarek, MD, PhD; Benjamin C. Creelan, MD; Thomas Sarkodie, MD; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(4):475-483. doi:10.1001/jamaoncol.2023.6789

This randomized clinical trial assesses the effect of pegargiminase-based chemotherapy on survival in patients with nonepithelioid pleural mesothelioma.

Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations

Joanne Kotsopoulos, PhD; Jacek Gronwald, MD, PhD; Tomasz Huzarski, MD, PhD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(4):484-492. doi:10.1001/jamaoncol.2023.6937

This cohort study evaluates the association between bilateral oophorectomy and all-cause mortality among women with BRCA1 or BRCA2 sequence variations.

Editorial
Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations
Meghna S. Trivedi, MD, MS; Katrina A. Armstrong, MD

JAMA Oncol

MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations

Jan Lubinski, MD, PhD; Joanne Kotsopoulos, PhD; Pal Moller, MD; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(4):493-499. doi:10.1001/jamaoncol.2023.6944

This cohort study examines the association between magnetic resonance imaging (MRI) surveillance and the risk of breast cancer mortality in women with BRCA1 or BRCA2 sequence variations.

Editorial
Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations
Meghna S. Trivedi, MD, MS; Katrina A. Armstrong, MD

JAMA Oncol

Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic

Todd Burus, MA, MAS; Feitong Lei, PhD; Bin Huang, DrPH, MS; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(4):500-507. doi:10.1001/jamaoncol.2023.6969

This cross-sectional analysis evaluates observed and expected cancer rate trends in the US to quantify the potentially undetected cancer cases associated with the COVID-19 pandemic response.

Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor鈥揚ositive Breast Cancer

Julieta Leone, MD; Michael J. Hassett, MD, MPH; Rachel A. Freedman, MD, MPH; et al.

Abstract Full Text

has audio

JAMA Oncol. 2024;10(4):508-515. doi:10.1001/jamaoncol.2023.7194

This cohort study examines the risk of mortality in men with vs without breast cancer鈥搒pecific mortality.

Podcast: Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor鈥揚ositive Breast Cancer

Brief Report

Association of Skin Microbiome Dynamics With Radiodermatitis in Patients With Breast Cancer

Claudia Hülpüsch, PhD; Avidan Uriel Neumann, PhD; Matthias Reiger, PhD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(4):516-521. doi:10.1001/jamaoncol.2023.6533

This observational study assesses the association of skin microbiome baseline composition and dynamics with the severity of radiodermatitis in patients undergoing adjuvant radiotherapy for breast cancer treatment.

Response to 2 Induction Courses of Bacillus Calmette-Gu猫rin Therapy Among Patients With High-Risk Non鈥揗uscle-Invasive Bladder Cancer: 5-year Follow-Up of a Phase 2 Clinical Trial

Andrew B. Katims, MD, MPH; Jacob Tallman, MD; Emily Vertosick, MPH; et al.

Abstract Full Text

JAMA Oncol. 2024;10(4):522-525. doi:10.1001/jamaoncol.2023.6804

This study of 5-year follow-up data from a phase 2 clinical trial examines the association of response with 12 induction instillations of bacillus Calmette-Gu猫rin (BCG) without maintenance therapy for patients with high-risk non鈥搈uscle-invasive bladder cancer (NMIBC).

Research Letter

Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition

Peter D. Zang, MD; Neal S. Chawla, MD; Regina Barragan-Carrillo, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(4):531-532. doi:10.1001/jamaoncol.2023.6817

This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.

Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

Mark Gurney, MB, BCh, BAO; Anmol Baranwal, MD; Allison Rosenthal, DO; et al.

Abstract Full Text

JAMA Oncol. 2024;10(4):532-535. doi:10.1001/jamaoncol.2023.7182

This case-control study examines the incidence and risks of myeloid neoplasms in adults treated for B-cell lymphoproliferative disorders or multiple myeloma.

Special Communication

Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access

Craig Underhill, MBBS; Jessica Freeman, MCLinExPhys; Jacqueline Dixon, RN; et al.

Abstract Full Text

has active quiz

JAMA Oncol. 2024;10(4):526-530. doi:10.1001/jamaoncol.2023.6565

This clinical care review summarizes government policies for the safe conduct of clinical trials using the telehealth and decentralized clinical trials digital health models.

Viewpoint

Federal Transportation Regulations Limit Access to Clinical Trials and Oncology Care

Sam Pancoe, MSc; Emily M. Ko, MD, MSCR; Anna Jo Bodurtha Smith, MD, MPH

Abstract Full Text

JAMA Oncol. 2024;10(4):425-426. doi:10.1001/jamaoncol.2023.6767

This Viewpoint discusses how improving accessibility to oncology services will lead to more equitable care for patients with cancer.

Modernize Precision Oncology With Decentralized Trial Tools

Muhammad Shaalan Beg, MD; Vivek Subbiah, MD

Abstract Full Text

JAMA Oncol. 2024;10(4):427-428. doi:10.1001/jamaoncol.2023.6786

This Viewpoint examines how modern precision oncology clinical trials, bolstered by decentralized trial tools, can enhance access to cancer treatments and reduce the burden of trial participation on clinics and participants.

Accreditation Standards鈥擜n Untapped Lever for Cancer Equity

Parsa Erfani, MD; Nishant Uppal, MD, MBA; Miranda B. Lam, MD, MBA

Abstract Full Text

JAMA Oncol. 2024;10(4):429-430. doi:10.1001/jamaoncol.2023.6811

This Viewpoint describes how the Commission on Cancer and the National Cancer Institute can incorporate health equity benchmarks into existing standards to improve care and outcomes for all patients with cancer.

Editorial

Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice

Elad Sharon, MD, MPH

Abstract Full Text

JAMA Oncol. 2024;10(4):433-434. doi:10.1001/jamaoncol.2023.5855

Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations

Meghna S. Trivedi, MD, MS; Katrina A. Armstrong, MD

Abstract Full Text

JAMA Oncol. 2024;10(4):435-436. doi:10.1001/jamaoncol.2023.5186

Hyperbaric Oxygen Therapy for Management of Late Radiation Toxicity鈥擜 Honey of a Trial?

Ezra Hahn, MD; Aron Popovtzer, MD; Benjamin W. Corn, MD

Abstract Full Text

JAMA Oncol. 2024;10(4):437-438. doi:10.1001/jamaoncol.2023.6698

Cancer Care Chronicles

Health and the 2024 US Election

The Threat of Florida鈥檚 New Legislation on Undocumented Individuals鈥擜 Call for Action

Coral Olazagasti, MD

Abstract Full Text

JAMA Oncol. 2024;10(4):431-432. doi:10.1001/jamaoncol.2023.6549

This essay describes the author鈥檚 experience with a patient that illustrates what undocumented individuals living in Florida are experiencing due to Bill 1718.

Poetry and Oncology